PathMaker launches first human trial to test noninvasive ALS device
PathMaker Neurosystems has launched a Phase 1 clinical trial that will test its experimental noninvasive nerve-modulating device in…
Articles by Marisa Wexler, MS
Ultomiris failed to show benefit in ALS in clinical trial, per full data
Treatment with Ultomiris (ravulizumab-cwvz) — a therapy approved for several rare diseases that works by blocking activation of part…
Bryostatin-1 boosts cell survival in lab model of ALS
Bryostatin-1, a molecule being developed to treat amyotrophic lateral sclerosis (ALS), improved cell survival in a lab model of…
TDP-43 more likely to clump if it can’t form two-protein complexes
When the TDP-43 protein is less able to form two-protein complexes called dimers, it appears to be more likely to form…
ALS mutation causes brain stem cell defects at early development
Mutations in the C9ORF7 gene, the most common genetic cause of amyotrophic lateral sclerosis (ALS), lead to defects in…
Transplanting motor neurons strengthens muscles in mouse model
Scientists have devised a technique for transplanting healthy motor neurons — the nerve cells that are lost in amyotrophic…
NEK1 gene mutations found to drive ALS in new study
Mutations in the gene NEK1, a major genetic cause of amyotrophic lateral sclerosis (ALS), may work to drive the disease…
More active innate immune system tied to faster ALS progression
People with amyotrophic lateral sclerosis (ALS) who have a more active innate immune system — the part of the…
Sleep problems are common among ALS patients: Meta-analysis
People with amyotrophic lateral sclerosis (ALS) spend time less asleep and wake up often during the night, a new…
New Brunswick adds Albrioza for ALS to its public health plan
New Brunswick is reimbursing, through its public health insurance program, the cost of Albrioza (sodium phenylbutyrate and ursodoxicoltaurine)…